Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Nearing retirement at 50? Discover wealth management strategies tailored to secure your financial future effectively.
21,324 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Rivian is plotting a bold three-year arc that hinges on scale, software, and partnerships. This guide breaks down the...
A high-stakes move by a leading investment manager has turned heads in the tech infrastructure space. This article ex...
Urban Outfitters’ namesake stores are lifting results as fourth-quarter earnings beat expectations, signaling a broad...
MannKind reported a double-digit revenue rise, but the stock still slid on Thursday. This article breaks down why the...
Quantum Computing Inc. (QUBT) is due to report Q4 2025 results after the market closes, with traders eyeing a narrow ...
Investors woke up to a modest rally in Intel as executives highlighted strong demand and expansion plans. This articl...
Freightcar America (Rail) earnings can signal the health of a cyclical market. This guide breaks down the numbers, si...
Campbell’s posts worst quarters as revenue and margins deteriorate across key segments. The company trims full-year t...
Mercer International posts a brutal Q4 hit from impairment, eroding equity, while International Paper pivots to highe...
When a high profile government move hits a new domain in the headlines, markets pay attention. This piece breaks down...
SoFi faced a high-profile attack from a famed short-seller, sending shares lower. This deep dive explains what the re...